Acceleron Pharma Inc. (NASDAQ:XLRN) SVP Ravindra Kumar sold 52,486 shares of the stock in a transaction on Monday, October 10th. The shares were sold at an average price of $33.92, for a total value of $1,780,325.12. Following the completion of the sale, the senior vice president now directly owns 91,875 shares of the company’s stock, valued at $3,116,400. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Shares of Acceleron Pharma Inc. (NASDAQ:XLRN) opened at 30.76 on Thursday. The company has a 50-day moving average price of $34.13 and a 200 day moving average price of $32.69. Acceleron Pharma Inc. has a one year low of $22.15 and a one year high of $50.86. The stock’s market cap is $1.16 billion.

Acceleron Pharma (NASDAQ:XLRN) last posted its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($0.59) EPS for the quarter, missing analysts’ consensus estimates of ($0.50) by $0.09. The firm had revenue of $3.20 million for the quarter, compared to analysts’ expectations of $3.77 million. Acceleron Pharma had a negative net margin of 190.41% and a negative return on equity of 30.00%. The company’s revenue was down 43.9% compared to the same quarter last year. Equities research analysts expect that Acceleron Pharma Inc. will post ($1.59) earnings per share for the current year.

Insider Buying and Selling by Quarter for Acceleron Pharma (NASDAQ:XLRN)

Several brokerages have recently issued reports on XLRN. Credit Suisse Group AG reaffirmed a “buy” rating on shares of Acceleron Pharma in a research report on Sunday, July 10th. FBR & Co reaffirmed a “buy” rating and set a $63.00 target price on shares of Acceleron Pharma in a research report on Friday, August 5th. Leerink Swann reaffirmed an “outperform” rating on shares of Acceleron Pharma in a research report on Friday, October 7th. BTIG Research began coverage on Acceleron Pharma in a research report on Friday, August 19th. They set a “buy” rating and a $46.00 target price for the company. Finally, Zacks Investment Research raised Acceleron Pharma from a “sell” rating to a “hold” rating in a research report on Wednesday. Two analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $47.11.

A number of hedge funds have recently bought and sold shares of the stock. Prudential Financial Inc. boosted its stake in Acceleron Pharma by 31.3% in the first quarter. Prudential Financial Inc. now owns 90,200 shares of the biopharmaceutical company’s stock worth $2,380,000 after buying an additional 21,500 shares during the period. BlackRock Inc. boosted its stake in Acceleron Pharma by 17.0% in the first quarter. BlackRock Inc. now owns 33,682 shares of the biopharmaceutical company’s stock worth $889,000 after buying an additional 4,887 shares during the period. BlackRock Group LTD boosted its stake in Acceleron Pharma by 63.6% in the first quarter. BlackRock Group LTD now owns 191,173 shares of the biopharmaceutical company’s stock worth $5,045,000 after buying an additional 74,285 shares during the period. BlackRock Fund Advisors boosted its stake in Acceleron Pharma by 16.2% in the first quarter. BlackRock Fund Advisors now owns 1,070,110 shares of the biopharmaceutical company’s stock worth $28,240,000 after buying an additional 149,193 shares during the period. Finally, BlackRock Institutional Trust Company N.A. boosted its stake in Acceleron Pharma by 16.4% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 646,645 shares of the biopharmaceutical company’s stock worth $17,065,000 after buying an additional 90,965 shares during the period. Institutional investors own 75.55% of the company’s stock.

About Acceleron Pharma

Acceleron Pharma Inc is a United States-based clinical stage biopharmaceutical company. The Company focuses on discovering and developing therapies to treat a range of diseases. Its therapeutic candidate, luspatercept, is being evaluated in Phase III studies for the treatment of the hematologic diseases myelodysplastic syndromes (MDS) and beta-thalassemia.

5 Day Chart for NASDAQ:XLRN

Receive News & Stock Ratings for Acceleron Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma Inc. and related stocks with our FREE daily email newsletter.